Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 5, pp 1680–1685 | Cite as

Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome

  • Chukwuemeka IhemelanduEmail author
  • Lana Bijelic
  • Paul H. Sugarbaker
Regional Cancer Therapies

Abstract

Background

Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive disease for which cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been used with remarkable survival benefits. Our aim was to analyze the clinicopathologic characteristics and prognosis of recurrent DMPM managed with iterative CRS and HIPEC.

Methods

A retrospective analysis of a prospectively maintained database for all patients treated for DMPM from 1989 to 2012.

Results

Of 205 consecutive CRS and HIPEC procedures, 44 (21.5 %) patients underwent an iterative procedure—22 (50.0 %) males versus 22 (50.0 %) females. Mean age at recurrence was 51.5 years. There was no 30-day mortality following an iterative procedure, and the grade III–V morbidity was 2.3 %. The median overall survival of patients undergoing an iterative CRS and HIPEC was 54 months versus 77 months following an initial CRS and HIPEC (p = 0.96). Patients undergoing an iterative surgery had a 3- and 5-year survival of 61 and 46 %, respectively, versus 60 and 52 % following an initial CRS and HIPEC. Amongst the iterative group, the achieved complete cytoreduction (CC) score was 15.9, 18.2, 22.7, and 43.2 % for CC0, CC1, CC2 and CC3, respectively, versus 3.1, 43.5, 28.6 and 24.8 %, respectively, following initial CRS (p = 0.000). Significant predictors of an improved survival in multivariate analysis were an epithelioid subtype, female sex, complete or near CC (CC0 or CC1), HIPEC regimen utilized, absence of postoperative complication, and age at diagnosis.

Conclusion

Iterative CRS and HIPEC can be performed safely and appear to have benefits with this group of patients showing an improved median survival.

Keywords

Pemetrexed Complete Cytoreduction Hyperthermic Intraperitoneal Chemotherapy Malignant Peritoneal Mesothelioma Early Postoperative Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Tanida S, Kataoka H, Kubota E, et al. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol. 2009;14(3):266–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Scripcariu V, Dajbog E, Radu I, et al. Malignant peritoneal mesothelioma tumors: evolution, treatment, prognosis [in Romanian]. Rev Med Chir Soc Med Nat Iasi. 2007;111(3):673–7.PubMedGoogle Scholar
  3. 3.
    Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.CrossRefPubMedGoogle Scholar
  5. 5.
    Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980;303:200–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Antman KH, Osteen RT, Klegar KL, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2(8462):977–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Turner K, Varghese S, Alexander HR. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Cancer. 2012;10:49–57.Google Scholar
  8. 8.
    Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Arch Surg. 1999;384:576–87.CrossRefGoogle Scholar
  9. 9.
    Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.CrossRefPubMedGoogle Scholar
  11. 11.
    Feldman AL, Libutti JF, Pingpank DL, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Sugarbaker P, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–691.CrossRefPubMedGoogle Scholar
  15. 15.
    Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999–1003.PubMedGoogle Scholar
  16. 16.
    Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–412.CrossRefPubMedGoogle Scholar
  17. 17.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Nash G, Otis CN. Protocol for the examination of specimens from patients with malignant pleural mesothelioma: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1999;123:39–44.PubMedGoogle Scholar
  19. 19.
    Yan T, Haveric N, Carmignani C, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–849.CrossRefPubMedGoogle Scholar
  20. 20.
    Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: Sugarbaker PH (ed). Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy. Textbook and Video Atlas. Woodbury; Cine-Med; 2012: pp. 1–30.Google Scholar
  21. 21.
    Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251–1261.CrossRefPubMedGoogle Scholar
  22. 22.
    Chua TC, Quinn LE, Zhao J, Morris DL. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol. 2013;108(2):81–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Votanopoulos K, Ihemelandu C, Shen P, et al. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215(3):412–7.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269–73.PubMedGoogle Scholar
  25. 25.
    Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107(6):566–73.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Chukwuemeka Ihemelandu
    • 1
    Email author
  • Lana Bijelic
    • 1
  • Paul H. Sugarbaker
    • 1
  1. 1.Program in Peritoneal Surface OncologyWashington Cancer InstituteWashingtonUSA

Personalised recommendations